利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.013 秒)

    RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF
    2.
    发明申请
    RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF 有权
    放射性混合物及其制造方法

    公开(公告)号：US20100183508A1

    公开(公告)日：2010-07-22

    申请号：US12354815

    申请日：2009-01-16

    申请人： Tsai-Yueh LUO ,  I-Chung Tang ,  Show-Wen Liu ,  Yu-Lung Wu ,  Cheng-Hsien Lin ,  Cheng-Fang Hsu ,  Kwei-Luen Hsu ,  Chang-Mau Sheng ,  Ching-Jun Liou ,  Te-Sheng Liang

    发明人： Tsai-Yueh LUO ,  I-Chung Tang ,  Show-Wen Liu ,  Yu-Lung Wu ,  Cheng-Hsien Lin ,  Cheng-Fang Hsu ,  Kwei-Luen Hsu ,  Chang-Mau Sheng ,  Ching-Jun Liou ,  Te-Sheng Liang

    IPC分类号： A61K51/04 ,  A61P35/00

    CPC分类号： A61K51/0478 ,  A61K49/0438

    摘要： A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4−/or ReO4−, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4−/or ReO4− avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.

    摘要翻译： 公开了放射性混合物及其制造方法。 通过胺胺 - 二硫化胺胺二齿螯合配体的MN系列化合物与TcO4-或ReO4-螯合反应形成放射性混合物（188Re-MN / Lipiodol混合物），然后溶解于Lipiodol中。 此外，TcO4- /或ReO4的99mTc /或188Re避免了由自由90Y引起的骨髓损伤。 通过长时间停留在肝肿瘤中的碘碘醇的特征，通过注射施用放射性混合物来治疗肝癌，从而可以预防外科手术引起的损伤。 188Re-MN / Lipiodol用于肝癌，乳腺癌或其他实体瘤治疗。 Re-188 MN或Re-188 MN / Lipiodol可与抗癌药物，水凝胶，脂质体，胶束或其他纳米颗粒混合，形成多功能治疗方式。

    Radioactive mixture and manufacturing method thereof
    4.
    发明授权
    Radioactive mixture and manufacturing method thereof 有权
    放射性混合物及其制造方法

    公开(公告)号：US08048405B2

    公开(公告)日：2011-11-01

    申请号：US12354815

    申请日：2009-01-16

    申请人： Tsai-Yueh Luo ,  I-Chung Tang ,  Show-Wen Liu ,  Yu-Lung Wu ,  Cheng-Hsien Lin ,  Cheng-Fang Hsu ,  Kwei-Luen Hsu ,  Chang-Mau Sheng ,  Ching-Jun Liou ,  Te-Sheng Liang

    发明人： Tsai-Yueh Luo ,  I-Chung Tang ,  Show-Wen Liu ,  Yu-Lung Wu ,  Cheng-Hsien Lin ,  Cheng-Fang Hsu ,  Kwei-Luen Hsu ,  Chang-Mau Sheng ,  Ching-Jun Liou ,  Te-Sheng Liang

    IPC分类号： A61K49/00

    CPC分类号： A61K51/0478 ,  A61K49/0438

    摘要： A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4−/or ReO4−, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4−/or ReO4− avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.

    摘要翻译： 公开了放射性混合物及其制造方法。 通过胺胺 - 二硫化胺胺二齿螯合配体的MN系列化合物与TcO4-或ReO4-螯合反应形成放射性混合物（188Re-MN / Lipiodol混合物），然后溶于Lipiodol中。 此外，TcO4- /或ReO4的99mTc /或188Re避免了由自由90Y引起的骨髓损伤。 通过长时间停留在肝肿瘤中的碘碘醇的特征，通过注射施用放射性混合物来治疗肝癌，从而可以预防外科手术引起的损伤。 188Re-MN / Lipiodol用于肝癌，乳腺癌或其他实体瘤治疗。 Re-188 MN或Re-188 MN / Lipiodol可与抗癌药物，水凝胶，脂质体，胶束或其他纳米颗粒混合，形成多功能治疗方式。

    Radioactive material for inhibiting cancer and preparation method thereof
    5.
    发明申请
    Radioactive material for inhibiting cancer and preparation method thereof 审中-公开
    用于抑制癌症的放射性物质及其制备方法

    公开(公告)号：US20090324496A1

    公开(公告)日：2009-12-31

    申请号：US12147733

    申请日：2008-06-27

    申请人： I-Chung TANG ,  Tasi-Yueh Luo ,  Yu-Lung Wu ,  Chang-Mau Sheng ,  Shan-Yun Cheng ,  Hsiu-Wen Liu ,  Yuen-Han Yeh ,  Wuu-Jyh Lin

    发明人： I-Chung TANG ,  Tasi-Yueh Luo ,  Yu-Lung Wu ,  Chang-Mau Sheng ,  Shan-Yun Cheng ,  Hsiu-Wen Liu ,  Yuen-Han Yeh ,  Wuu-Jyh Lin

    IPC分类号： A61K51/00 ,  A61P35/00

    CPC分类号： A61K51/1051 ,  A61K51/1093

    摘要： A radioactive material for inhibiting cancer and a preparation method thereof are disclosed. The radioactive material for inhibiting cancer is M-SOCTA-Z and M is a radioactive nuclide such as 188Re or 99mT while Z is protein or peptides having amino acid with NH or NH2 group. The preparation method of the radioactive material for inhibiting cancer includes steps of: reacting SOCTA with protein or peptide. Ester (—COOR) in SOCTA reacts with amines (—NH, —NH2) in protein or peptide to form peptide bond. Thus SOCTA-protein or SOCTA-peptide complex is produced. Then these SOCTA-protein complex reacts with radioactive nuclide M so as to generate M-SOCTA-protein or M-SOCTA-peptide. In an embodiment of the present invention, monoclonal antibody Herceptin is applied to bind with SOCTA and in combination with radiation-based therapy, effects of cancer treatment (such as breast cancer) are enhanced.

    摘要翻译： 公开了一种抑制癌症的放射性物质及其制备方法。 用于抑制癌症的放射性物质是M-SOCTA-Z，M是188Re或99mT的放射性核素，而Z是具有氨基酸与NH或NH 2基团的蛋白质或肽。 用于抑制癌症的放射性物质的制备方法包括以下步骤：使SOCTA与蛋白质或肽反应。 SOCTA中的酯（-COOR）与蛋白质或肽中的胺（-NH，-NH2）反应形成肽键。 因此产生SOCTA蛋白或SOCTA-肽复合物。 然后这些SOCTA-蛋白质复合物与放射性核素M反应，产生M-SOCTA-蛋白或M-SOCTA-肽。 在本发明的一个实施方案中，应用单克隆抗体赫赛汀与SOCTA结合，并结合放射治疗，增强了癌症治疗（如乳腺癌）的效果。